- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03082703
Impact of Text Messaging in the Management of Non-alcoholic Fatty Liver Disease
March 13, 2017 updated by: Ashwani Singal,MD
This randomized study aims at examining the impact of text messaging in the management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a disease frequently associated with obesity and varying components of metabolic syndrome including diabetes mellitus, hypertension, and dyslipidemia.
With rising incidence of obesity in the US, NAFLD and NASH are rapidly increasing with currently the second etiology for liver transplantation in the US.
The objectives of this protocol are to a) prospectively enroll patients with NAFLD and NASH; b) randomize them to receiving text messaging to help manage obesity and other components od metabolic syndrome in addition to standard clinical care or receiving only standard clinical care; and c) follow up these patients at the end of 3 months period for weight loss, blood pressure control, HBA1c, and liver enzymes.
The immediate aim of this protocol is to develop the pilot data on the usefulness of text messaging in the management of NAFLD and NASH.
The long-term goals of this research are to establish text messaging as a beneficial intervention in the management of weight loss and control of risk factors of NAFLD and improve outcomes of these patients with NAFLD and NASH.
Study Overview
Detailed Description
Patients will be recruited primarily from the outpatient Liver Kirklin Clinic setting.
- Informed consent will be obtained by one of the investigators named in the protocol or by research coordinators involved with the study
- Eligibility will be confirmed by interview and review of medical records using the inclusion and exclusion criteria as listed above.
- Complete history and physical examination will be recorded especially for weight and body mass index, associated components of metabolic syndrome (diabetes, hypertension, and dyslipidemia), liver enzymes, and current medications list.
- All procedures such as imaging, endoscopy, and liver biopsy will be done as part of standard routine care of these patients and no procedure will be done as part of this research study.
- Patients would be randomized to standard clinical care or to text messaging in addition to standard clinical care. Standard clinical care includes obtaining data on history and physical examination, routine blood work as part of liver disease care, ultrasound and appropriate any other liver imaging as needed for patient care, counseling for at least 7-10% weight loss with discussion on strategies to achieve this, management of other risk factors including diabetes, hypertension, and dyslipidemia, and counseling for compliance to taking medications and following up on future clinic visits. The study investigator would be blinded to the randomization and which group the patient is randomized to.
- Patients would be followed at the end of 6 months period for assessing the study outcomes as detailed earlier. Follow up for patients with stable liver disease is usually done every 3-6 months. No additional clinic visits would be needed for this study.
- During these 6 months, patients would receive standard text messages as detailed later. Patients will use their own cell phone to receive the text messages and reply to these messages. There will be no additional intervention or device needed for this study
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a diagnosis of NAFLD or NASH as determined with presence of steatosis and/or elevated liver enzymes, exclusion of other causes of liver disease, and history of alcohol use less than 10 g/d.
- Age >18 years
- Established patient at the UAB Kirklin clinic for at least 3-6 months
- Ownership of cell phone with text messaging service
- Ability to read and send text message
Exclusion Criteria:
- Failure to meet the inclusion criteria.
- Any medical, psychiatric, or social conditions that, in the opinion of the investigators, would make participation in this protocol not in the best interest of the subject
- Refusal to consent for the study
- Pregnant females
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control
|
|
EXPERIMENTAL: Text Messaging
|
Subjects contacted 3 times weekly via text messaging for the study period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in weight
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 24, 2016
Primary Completion (ACTUAL)
December 1, 2016
Study Completion (ACTUAL)
March 1, 2017
Study Registration Dates
First Submitted
March 13, 2017
First Submitted That Met QC Criteria
March 13, 2017
First Posted (ACTUAL)
March 17, 2017
Study Record Updates
Last Update Posted (ACTUAL)
March 17, 2017
Last Update Submitted That Met QC Criteria
March 13, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- X150420005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NAFLD and NASH
-
Fibronostics USA, IncOBVIO HEALTH USA, Inc.Withdrawn
-
University of Wisconsin, MadisonRecruiting
-
Active Genomes Expressed Diagnostics, CorpWalter Reed National Military Medical Center; Arizona Clinical TrialsNot yet recruitingHealthy | NAFLD | NASH With FibrosisUnited States
-
1Globe Biomedical Co., Ltd.Recruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingFibrosis | Cirrhosis | NAFLD | NASH - Nonalcoholic Steatohepatitis | NASH
-
AlbireoCompleted
-
Indiana UniversitySonic IncytesTerminatedNAFLD | NASH - Nonalcoholic SteatohepatitisUnited States
-
University of AarhusCompleted
-
HBI Solutions Inc.mProbe Inc.Not yet recruitingNAFLD | NASH - Nonalcoholic Steatohepatitis
-
Russian Academy of Medical SciencesFederal State Budgetary Scientific Institution "Federal Research Centre of...UnknownNAFLD | NASH - Nonalcoholic SteatohepatitisRussian Federation
Clinical Trials on Text Messaging
-
University of Colorado, DenverNational Institute of Mental Health (NIMH)CompletedHIV InfectionsUnited States
-
VA Office of Research and DevelopmentVA Office of Connected CareCompleted
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingCOVID-19United States
-
University of StellenboschUniversity of British Columbia; McMaster UniversityCompletedText Messaging Plus Motivational Interviewing in Promotion of Breastfeeding Among HIV-infected WomenHIV Infections | Breast FeedingSouth Africa
-
University of RochesterCompleted
-
University of MichiganCompletedStroke | Hypertension
-
University of Nebraska LincolnThe Methodist Hospital Research InstituteCompletedDiabetes Mellitus, Type 2United States
-
China National Center for Cardiovascular DiseasesCompleted
-
University of MichiganCompletedStroke | HypertensionUnited States